Investor Relations

 

Transcat (Nasdaq:TRNS) has been a leader in the test and measurement industry for over 40 years. We strive to differentiate ourselves and build barriers to competitive entry by offering the best products, delivering high quality calibration and repair services, and integrating those products and services. We work diligently to create lasting value for our shareholders.

Strategy

Our strategy is to continue to grow our business through a blend of organic revenue growth and acquisitions. We leverage the complementary nature of our operating segments in ways that add value for all customers who select Transcat as their source for test and measurement equipment and/or calibration and laboratory instrument services. We believe our combined Service and Distribution segment offerings, experience, technical expertise and quality-oriented, integrity-based approach create a unique and compelling value proposition for our customers. We strive to differentiate ourselves within the markets we serve and build barriers to competitive entry by offering a broad range of the best products and services, and integrating those products and services to benefit our customers’ operations.

Annual Reports

Get access to Transcat’s annual reports, read meeting transcripts and view annual report presentations

Earnings Releases

View Transcat’s earnings releases, listen to presentation webcasts or view the presentation slides

Corporate Governance

View Transcat's corporate governance guidelines, board of directors, executive officers and senior management

Recent Company News

Transcat Reports Third Quarter Operating Income Increase of 20% on Solid Service Organic Growth and Gross Margin Expansion

  • Total revenue of $44.1 million up 2% from prior-year period in an environment that continues to be impacted by the COVID-19 pandemic
  • Service segment organic revenue growth of 5.9%; Total Service revenue up 12.2%
  • Service segment gross margin expanded 590 basis points to 27.9%

ROCHESTER, NY, February 2, 2021 – Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, today reported financial results for its third quarter and nine-month period ended December 26, 2020 (the “third quarter”) of fiscal year 2021, which ends March 27, 2021 (“fiscal 2021”). Results include the previously reported acquisition of TTE Laboratories, Inc. (referred to as “pipettes.com”) effective February 21, 2020 and the acquisition of BioTek Services, Inc. (“BioTek”) effective December 16, 2020.

Transcat Announces Third Quarter Fiscal Year 2021 Conference Call and Webcast

ROCHESTER, NY, January 20, 2021 – Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it will release its third quarter fiscal year 2021 results after the close of financial markets on Tuesday, February 2, 2021.

Transcat, Inc. Expands Life Science Market Penetration with BioTek Services, Inc. Acquisition

ROCHESTER, NY, December 16, 2020 – Transcat, Inc. (Nasdaq: TRNS) (“Transcat” or the “Company”), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it has acquired substantially all of the assets of BioTek Services, Inc. (“BioTek”), effective December 16, 2020. The purchase price was $3.5 million and is subject to certain customary holdback provisions.

For further information, please contact:

Deborah Pawlowski
Kei Advisors
7606 Transit Road
Suite 300
Buffalo, NY 14221
Phone: 716.843.3908
Email: dpawlowski@keiadvisors.com

Mark A. Doheny
CFO
35 Vantage Point Drive
Rochester, NY 14624
Phone: 585.714.3617
Email: mark.doheny@transcat.com